GW to raise $179M, KDEV’s portfolio value sinks to new low, BIA wants U.K. to rival CA, MA

Nick Paul Taylor In this week's EuroBiotech Report, GW Pharmaceuticals is once again turning to U.S. investors to fuel the advance of its cannabis-based pipeline. The latest offering ...

Shire’s binge-eating push on Vyvanse feeds Q1 earnings beat

Carly Helfand When Vyvanse in February won the FDA's first-ever approval for binge eating disorder (BED), Shire predicted the indication could help the med rake ...

FDA panel gives a thumbs up to Amgen’s T-Vec for melanoma

John Carroll Amgen's regulatory team for talimogene laherparepvec (T-Vec) was grilled by a group of outside FDA experts who picked up on some major questions regarding ...

Ex-Sanofi exec Whitaker lands at Valeant in EVP role

Carly Helfand After departing from Sanofi last year for the CEO's chair at Synta Pharmaceuticals, Anne Whitaker is now moving on to Valeant, where she'll step into the role ...

As patent battle brews, Celgene and GSK lead $64M raise for CRISPR Therapeutics

John Carroll The cascade of venture cash into CRISPR-Cas9 startups is continuing with no end in sight, despite a patent brawl brewing over who owns the technology. Today it's CRISPR ...

Mylan recalls injectable cancer meds, most produced for Pfizer

Tracy Staton Mylan is recalling 8 lots of injectable cancer drugs, most of them manufactured for Pfizer, after particulate was discovered in vials. FiercePharma News

Google’s Calico continues its partnering romp on aging R&D with Buck collaboration

John Carroll FierceBiotech News

FDA opens floodgates to generics of Bristol-Myers’ Abilify

Eric Palmer Just hours after Bristol-Myers Squibb beat Wall Street expectations with earnings that got a goose from antipsychotic Abilify, the FDA opened the floodgates to generics ...

FDA reviewers raise red flags for Amgen cancer vaccine ahead of AdComm

Carly Helfand Wednesday's a big day for Amgen, whose dual-acting cancer vaccine/viral therapy is coming up for review by an FDA panel of experts. FiercePharma News

Roche’s $100M Alzheimer’s study could shift the balance in R&D

Damian Garde Despite all the excitement over Biogen's recent Phase I success in Alzheimer's, the question of whether attacking protein buildups in the brain can in fact treat ...

Eyeing big niche in obesity, Novo rolls out Saxenda at $1,000 per month

Tracy Staton Novo Nordisk says its new drug Saxenda has a niche in the U.S. obesity market. Now, the Danish drugmaker has the chance to prove it. Saxenda is rolling out ...

MaxCyte buys into CAR-T with Johns Hopkins partnership

Damian Garde Maryland biotech MaxCyte is delving into the world of CAR-T treatments for cancer, teaming up with Johns Hopkins University on a preclinical program. FierceBiotech News
Page 1 of 3123
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS